Found 6 clinical trials
9-ING-41 Plus Retifanlimab and Gemcitabine/Nab-Paclitaxel in Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)
To determine the rate of disease control of the combination of 9-ING-41 and retifanlimab plus gemcitabine/nab-paclitaxel in patients with pancreatic cancer without prior systemic therapy for
- 0 views
- 23 Mar, 2022
- 1 location
Actuate 1901: 9-ING-41 in Myelofibrosis
9-ING-41 has anti-cancer clinical activity while not causing myelosuppression, and has both pre-clinical anti-fibrotic activity and activity against myelofibrosis. This Phase 2 study will study
- 23 views
- 13 May, 2022
- 9 locations
FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer
of the study drugs involved in this study are: 9-ING-41 Losartan Ferumoxytol FOLFIRINOX (made up of 4 different drugs): 5-Fluorouracil (5-FU
- 0 views
- 17 Jun, 2022
- 1 location
9-ING-41 in Patients With Advanced Cancers
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β
- 795 views
- 29 May, 2022
- 10 locations
9-ING-41 in Pediatric Patients With Refractory Malignancies.
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
- 0 views
- 14 May, 2022
- 8 locations
Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma
This trial is investigating an intravenous (IV) medication called 9-ING-41 in combination with chemotherapy (carboplatin) for the treatment of advanced salivary gland cancers. The names
- 0 views
- 21 Oct, 2022
- 2 locations